Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 0.68 |
| ▸ | TP53 | P04637 | 3/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | HTR2B | P41595 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 5/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.64 |
| ▸ | NPC1 | O15118 | 5/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | GAA | P10253 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.58 |
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenindione SCHEMBL29388073 | 0.81 | MAPT (1.00) | RAB9AMAPTTP53LMNAMAPK1 | |
| Phenindione SCHEMBL33831 | 0.81 | MAPT (1.00) | RAB9AMAPTTP53LMNAMAPK1 | |
| SCHEMBL10620936 | 0.81 | RAB9A (0.67) | RAB9AMAPTTP53LMNAMAPK1 | |
| SCHEMBL14939892 | 0.80 | RAB9A (0.67) | RAB9AMAPTTP53LMNAMAPK1 | |
| SCHEMBL17525348 | 0.80 | MAPT (0.71) | RAB9AMAPTTP53LMNAMAPK1 | |
| SCHEMBL10620960 | 0.80 | RAB9A (0.66) | RAB9AMAPTTP53LMNAMAPK1 | |
| Phenindione SCHEMBL1443973 | 0.79 | MAPT (0.95) | RAB9AMAPTTP53LMNAMAPK1 | |
| Phenindione SCHEMBL6827577 | 0.79 | MAPT (0.95) | RAB9AMAPTTP53LMNAMAPK1 | |
| SCHEMBL10559114 | 0.79 | MAPT (0.95) | RAB9AMAPTTP53LMNAMAPK1 | |
| SCHEMBL5649473 | 0.78 | KMT2A (1.00) | RAB9AMAPTTP53LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1591 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11421234-B2 | Aptamers for targeting coagulation factor XIII and uses thereof | CHANG GUNG UNIVERSITY (TW) | 2022-08-23 | — | — | US | claimed |
| EP-3964208-A1 | COMPOSITION COMPRISING ISOQUERCETIN FOR TREATING VENOUS THROMBOSIS | Quercegen Pharmaceuticals LLC (US) | 2022-03-09 | — | — | EP | claimed |
| US-20210371512-A1 | Use of IL-1 beta Binding Antibodies | NOVARTIS AG (CH) | 2021-12-02 | — | — | US | claimed |
| US-20210163945-A1 | APTAMERS FOR TARGETING COAGULATION FACTOR XIII AND USES THEREOF | CHANG GUNG UNIVERSITY (TW) | 2021-06-03 | — | — | US | claimed |
| WO-2021054927-A2 | GLUTATHIONE-CHOLESTEROL DERIVATIVES AS BRAIN TARGETING AGENTS | SOUTH DAKOTA BOARD OF REGENTS (US) | 2021-03-25 | — | — | WO | claimed |
| US-20200147264-A1 | DETECTION OF BIOPROSTHETIC VALVE DEGENERATION | ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (FR) | 2020-05-14 | — | — | US | claimed |
| US-20200048305-A1 | GLUTATHIONE-CHOLESTEROL DERIVATIVES AS BRAIN TARGETING AGENTS | SOUTH DAKOTA BOARD OF REGENTS (US) | 2020-02-13 | — | — | US | claimed |
| EP-3100728-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME | CYDEX PHARMACEUTICALS INC (US) | 2019-11-20 | — | — | EP | claimed |
| US-10391096-B2 | Method for treating thrombotic disorders using quercetin-containing compositions | QUERCEGEN PHARMACEUTICALS LLC (US) | 2019-08-27 | — | — | US | claimed |
| US-20180177759-A1 | COMBINATION OF AN ANTIANDROGEN WITH A VITAMIN K ANTAGONIST OR WITH A GAMMA-GLUTAMYL CARBOXYLASE INHIBITOR FOR THE THERAPY OF ANDROGEN RECEPTOR POSITIVE CANCER | CEMM - FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GMBH (AT) | 2018-06-28 | — | — | US | claimed |
| US-20020173818-A1 | Delivering an agent to a patient's body | BOSTON SCIENTIFIC SCIMED, INC. | 2002-11-21 | — | — | US | claimed |
| WO-2002091957-A1 | DELIVERING AN AGENT TO A PATIENT'S BODY | SCIMED LIFE SYSTEM, INC. (US) | 2002-11-21 | — | — | WO | claimed |
| WO-2002049649-A2 | PHARMACEUTICAL FORMULATION CONTAINING THIENOPYRIMIDINES AND ANTITHROMBOTICS, CALCIUM ANTAGONISTS, PROSTAGLANDINS OR PROSTAGLANDIN DERIVATIVES (2) | MERCK PATENT GMBH (DE) | 2002-06-27 | — | — | WO | claimed |
| WO-2002049650-A2 | PHARMACEUTICAL FORMULATION CONTAINING THIENOPYRIMIDINES AND ANTITHROMBOTICS, CALCIUM ANTAGONISTS, PROSTAGLANDINS OR PROSTAGLANDIN DERIVATIVES | MERCK PATENT GMBH (DE) | 2002-06-27 | — | — | WO | claimed |
| WO-2002049651-A1 | PHARMACEUTICAL FORMULATION CONTAINING PYRAZOLO[4,3-D]PYRIMIDINES AND ANTITHROMBOTIC AGENTS, CALCIUM-ANTAGONISTS, PROSTAGLANDINS OR PROSTAGLANDIN DERIVATIVES | MERCK PATENT GMBH (DE) | 2002-06-27 | — | — | WO | claimed |
| EP-1100479-A1 | MEDICINAL PRODUCTS WITH RETARDED PHARMACOLOGICAL ACTIVITY AND METHOD FOR THE PRODUCTION THEREOF | Schierholz, Jörg, Dr.Dr. (DE) | 2001-05-23 | — | — | EP | claimed |
| EP-0985413-A1 | Medical articles with sustained pharmacological activity and process for their preparation | Schierholz, Jörg Michael, Dr. Dr. (DE) | 2000-03-15 | — | — | EP | claimed |
| WO-2000007574-A1 | MEDICINAL PRODUCTS WITH RETARDED PHARMACOLOGICAL ACTIVITY AND METHOD FOR THE PRODUCTION THEREOF | SCHIERHOLZ JOERG (DE) | 2000-02-17 | — | — | WO | claimed |
| EP-0088051-B1 | RODENTICIDAL BAIT | CIBA-GEIGY AG (CH) | 1986-11-12 | — | — | EP | claimed |
| EP-0088051-A1 | Rodenticidal bait | CIBA-GEIGY AG (CH) | 1983-09-07 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048305-A1 | GLUTATHIONE-CHOLESTEROL DERIVATIVES AS BRAIN TARGETING AGENTS | GSTK1, GSTO1, GSTM2 | RAB9A 1626/4885MAPT 1050/4885TP53 4095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.